These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24378973)

  • 1. Activity of thrombin-activatable fibrinolysis inhibitor in the plasma of patients with abdominal aortic aneurysm.
    Dubis J; Zuk N; Grendziak R; Zapotoczny N; Pfanhauser M; Witkiewicz W
    Blood Coagul Fibrinolysis; 2014 Apr; 25(3):226-31. PubMed ID: 24378973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombin-activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease.
    Bridge KI; Bollen L; Zhong J; Hesketh M; Macrae FL; Johnson A; Philippou H; Scott DJ; Gils A; Ariёns RAS
    J Thromb Haemost; 2017 Nov; 15(11):2218-2225. PubMed ID: 28834317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of tissue factor in patients undergoing open repair of ruptured and nonruptured abdominal aortic aneurysms.
    Hobbs SD; Haggart P; Fegan C; Bradbury AW; Adam DJ
    J Vasc Surg; 2007 Oct; 46(4):682-6. PubMed ID: 17764874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N; Guldiken S; Demir M; Tugrul A
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in thrombin generation, fibrinolysis, platelet and endothelial cell activity, and inflammation following endovascular abdominal aortic aneurysm repair.
    Abdelhamid MF; Davies RS; Adam DJ; Vohra RK; Bradbury AW
    J Vasc Surg; 2012 Jan; 55(1):41-6. PubMed ID: 21975058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
    Wada T; Gando S; Mizugaki A; Yanagida Y; Jesmin S; Yokota H; Ieko M
    Thromb Res; 2013 Jul; 132(1):e64-9. PubMed ID: 23726093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
    Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P; Kotuličová D; Staško J; Kubisz P
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated tissue plasminogen activator in patients with screening-detected abdominal aortic aneurysm.
    Wanhainen A; Nilsson TK; Bergqvist D; Boman K; Björck M
    J Vasc Surg; 2007 Jun; 45(6):1109-13. PubMed ID: 17543671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinolysis in patients with an abdominal aortic aneurysm with special emphasis on rupture and shock.
    Skagius E; Siegbahn A; Bergqvist D; Henriksson AE
    J Thromb Haemost; 2008 Jan; 6(1):147-50. PubMed ID: 17922806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haemostatic factors and intraluminal thrombus thickness in abdominal aortic aneurysm. Is secondary fibrinolysis relevant?
    Siennicka A; Drozdzynska M; Chelstowski K; Cnotliwy M; Jastrzebska M
    J Physiol Pharmacol; 2013 Jun; 64(3):321-30. PubMed ID: 23959729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
    Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
    Colucci M; Binetti BM; Branca MG; Clerici C; Morelli A; Semeraro N; Gresele P
    Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
    Akinci B; Comlekci A; Yener S; Demir T; Ozcan MA; Bayraktar F; Yesil S
    Endocr J; 2007 Aug; 54(4):593-9. PubMed ID: 17690487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
    Shantsila E; Montoro-García S; Tapp LD; Apostolakis S; Wrigley BJ; Lip GY
    Thromb Haemost; 2012 Jul; 108(1):32-40. PubMed ID: 22538774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers of proteolysis, fibrinolysis, and coagulation in relation to size and growth rate of abdominal aortic aneurysms.
    Flondell-Sité D; Lindblad B; Kölbel T; Gottsäter A
    Vasc Endovascular Surg; 2010 May; 44(4):262-8. PubMed ID: 20356864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy.
    Akinci B; Demir T; Saygili S; Yener S; Alacacioglu I; Saygili F; Bayraktar F; Yesil S
    Diabetes Res Clin Pract; 2008 Jul; 81(1):93-6. PubMed ID: 18406001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myocardial injury and systemic fibrinolysis in patients undergoing repair of ruptured abdominal aortic aneurysm: a preliminary report.
    Haggart PC; Adam DJ; Ludman PF; Ludman CA; Bradbury AW
    Eur J Vasc Endovasc Surg; 2001 Jun; 21(6):529-34. PubMed ID: 11397027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C; Kocak M; Nuhoglu I; Yilmaz M; Ucuncu O
    Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system.
    Danese S; Papa A
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):826-8. PubMed ID: 18794594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.